1. Home
  2. DD vs RMD Comparison

DD vs RMD Comparison

Compare DD & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DuPont de Nemours Inc.

DD

DuPont de Nemours Inc.

HOLD

Current Price

$41.30

Market Cap

17.1B

Sector

Industrials

ML Signal

HOLD

Logo ResMed Inc.

RMD

ResMed Inc.

HOLD

Current Price

$244.67

Market Cap

36.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DD
RMD
Founded
2015
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.1B
36.4B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
DD
RMD
Price
$41.30
$244.67
Analyst Decision
Buy
Buy
Analyst Count
12
13
Target Price
$64.33
$289.09
AVG Volume (30 Days)
5.3M
1.0M
Earning Date
02-10-2026
01-29-2026
Dividend Yield
1.94%
0.98%
EPS Growth
N/A
29.59
EPS
N/A
9.77
Revenue
$12,843,000,000.00
$5,257,400,000.00
Revenue This Year
N/A
$9.85
Revenue Next Year
$3.36
$7.32
P/E Ratio
$23.79
$25.07
Revenue Growth
15.07
9.36
52 Week Low
$33.34
$199.92
52 Week High
$85.00
$293.81

Technical Indicators

Market Signals
Indicator
DD
RMD
Relative Strength Index (RSI) 40.23 42.21
Support Level $40.20 $241.66
Resistance Level $41.83 $255.83
Average True Range (ATR) 0.80 5.07
MACD 1.11 -0.45
Stochastic Oscillator 83.86 18.58

Price Performance

Historical Comparison
DD
RMD

About DD DuPont de Nemours Inc.

DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the healthcare, water, construction, automotive, aerospace, and printing and packaging industries. Healthcare and water will generate the majority of profits.

About RMD ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Share on Social Networks: